arrow
A

Astrid A.M. van der Veldt

Erasmus Medical Center
H指数:44
被引数:6,856

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results

I期[177Lu]Lu-NeoB在过度表达胃泌素释放肽受体的晚期实体瘤患者中的研究:初步安全性和剂量学结果

2026-02-010
PRE
Preoperative ultrasound before sentinel lymph node biopsy in melanoma in the era of neoadjuvant treatment: a systematic review and meta-analysis of diagnostic performance and cost analysis

新辅助治疗时代黑色素瘤前哨淋巴结活检前的术前超声检查: 诊断性能和成本分析的系统评价和荟萃分析

2026-01-270
OAAI
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma

使用BRAF/MEK抑制剂进行诱导治疗与一线使用ipilimumab/nivolumab治疗预后不良的晚期黑色素瘤

2025-10-200
OAAI
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

COVID-19疫苗在血液系统恶性肿瘤患者中的有效性:一项全国性队列研究

2025-10-010
OAAI
Modified OPTIModel with oligometastatic disease for the prediction of overall survival of patients with renal cell cancer and symptomatic long bone metastases

改良的OPTIModel模型结合寡转移性疾病,用于预测肾细胞癌合并症状性长骨转移患者的总生存期。

2025-09-020
OAAI
Targeted Therapy for Rare BRAF-Mutated Melanoma: Updated Multicenter Analysis and Launch of a Publicly Accessible Online Outcome Database

靶向治疗罕见BRAF突变黑色素瘤:更新后的多中心分析及公共可访问在线结局数据库的建立

2025-08-090
PRE
From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)

从ICI到ICU:对接受免疫检查点抑制剂(ICI)治疗并入住重症监护室(ICU)的实体瘤患者的系统综述

2025-05-010
OAAI
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy

在既往接受过ipilimumab为基础治疗方案的患者中,对晚期黑色素瘤患者进行ipilimumab和nivolumab的重新挑战治疗

2025-04-290
PRE
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis

辅助BRAF/MEK与抗PD-1在BRAF突变黑色素瘤中的倾向性评分匹配生存分析

2025-04-150
PRE
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model

荷兰使用卫生经济模型评估BRAF突变型晚期黑色素瘤治疗顺序的成本效益

2025-03-010
PRE
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

开发决策模型以估计晚期黑色素瘤治疗序列的结果

2025-02-221
OAAI
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry [Eur. J. Cancer 212, 2024, 115056]

辅助免疫疗法在III期和已切除IV期黑色素瘤老年患者中的应用:来自荷兰黑色素瘤治疗登记研究的毒性和无复发生存结果 [Eur. J. Cancer 212, 2024, 115056]

2025-02-010
PRE